Who Owns Health Catalyst Company?

Who Owns Health Catalyst?

Health Catalyst, a key player in healthcare data and analytics, was founded in 2008. Its mission is to drive data-informed improvements in healthcare, aiming to enhance outcomes and reduce costs.

The company's journey from its founding to its current status as a publicly traded entity reveals a dynamic ownership landscape. Understanding who holds the reins is vital for grasping its strategic trajectory.

Health Catalyst is now a publicly traded company on the NASDAQ under the ticker HCAT. As of July 2025, it has around 1,500 employees and reported a trailing 12-month revenue of $311 million as of March 31, 2025. Its solutions, including those that contribute to its Health Catalyst BCG Matrix analysis, have earned accreditations for security and innovation in 2024.

Health Catalyst was established in 2008 by its co-founders, Tom Burton and Steven Barlow. Burton, who also serves as President of Professional Services, brings extensive experience in business intelligence and analytics, having been instrumental in Intermountain Healthcare's advancements in care quality and cost reduction. Barlow is also a key co-founder of the company.

Founding Vision

The company's inception was driven by a vision to transform healthcare through data and analytics. This core mission attracted significant backing from early investors.

Early Funding

Prior to its public offering, Health Catalyst secured a substantial $392 million in funding across 10 distinct rounds. This capital infusion was crucial for its growth and development.

Key Early Investors

Prominent institutional investors in the early stages included Norwest Venture Partners, Sequoia Capital, and Kaiser Permanente Ventures. Brent James also provided support as an angel investor.

Corporate Evolution

The company was initially incorporated as HQC Holdings, Inc. in September 2011. It later officially changed its name to Health Catalyst, Inc., reflecting its evolving identity.

Founders' Roles

Tom Burton continues to play a vital role as President of Professional Services, leveraging his deep expertise. Steven Barlow also remains a co-founder, contributing to the company's strategic direction.

Venture Capital Backing

The significant venture capital backing received by Health Catalyst underscores the strong belief in its data-driven approach to healthcare improvement. This support was pivotal in its early trajectory.

While the precise initial equity distribution among the founders and early stakeholders is not publicly disclosed, the substantial funding rounds indicate a broad base of support. The company's commitment to its founding principles is evident in its continued focus on data analytics for healthcare advancement, aligning with the Mission, Vision & Core Values of Health Catalyst.

Complete Health Catalyst Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Health Catalyst's journey from a private venture to a public entity significantly reshaped its ownership landscape. The company's Initial Public Offering (IPO) on July 25, 2019, marked a pivotal moment, transitioning ownership to a broader base of public and institutional investors.

The ownership structure of Health Catalyst has evolved considerably since its inception. As of July 25, 2025, the company has 69.60 million shares outstanding, with institutional investors holding a substantial majority. As of March 31, 2025, 358 institutional owners collectively held 65,393,653 shares, representing approximately 93.95% of the total shares, excluding those reported under 13D/G filings. This indicates a strong presence of large investment firms in the Health Catalyst stakeholders group.

Key Health Catalyst Institutional Investors

Major institutional investors play a crucial role in Health Catalyst's stock ownership breakdown. These firms manage significant assets and influence the company's direction through their investment decisions.

• First Light Asset Management, LLC
• BlackRock, Inc.
• The Vanguard Group, Inc.
• Impax Asset Management Group plc
• Wellington Management Group Llp
• Primecap Management Co/Ca/
• Dimensional Fund Advisors Lp
• Nepsis, Inc.

While the specific stakes of founders are not consistently detailed in public filings post-IPO, the executive leadership remains actively involved. Dan Burton, for instance, serves as the Chief Executive Officer and a Director, underscoring management's continued commitment. The company's financial performance, with trailing 12-month revenue ending March 31, 2025, at $311.27 million and a projected full-year 2025 revenue of around $335 million, supports its growth trajectory and attractiveness to investors. Understanding the Target Market of Health Catalyst is key to appreciating the company's strategic positioning and investor appeal.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

The current Board of Directors for Health Catalyst includes key figures such as Dan Burton (Chief Executive Officer) and John A. Kane (Chairman of the Board). Dr. Jill Hoggard Green joined the board on December 1, 2024, bringing valuable experience as the former CEO of The Queens Health System. Anita Pramoda concluded her tenure on the board on March 1, 2025, after approximately ten years of service.

Health Catalyst operates under a one-share-one-vote system for its common stock, meaning each share grants its holder a single vote on all matters presented to stockholders, including director elections. The company's governance structure does not permit cumulative voting rights for director elections. According to the company's Restated Certificate and Restated Bylaws, all stockholder actions must take place during a properly called meeting, and only the board of directors has the authority to convene a special meeting. Significant changes to the Restated Certificate require approval from 66 2/3% of stockholders. Similarly, amendments to the Restated Bylaws by stockholders necessitate a 66 2/3% vote, unless the Board of Directors recommends approval, in which case a simple majority suffices. The board itself can alter or revoke the bylaws with an affirmative vote from a majority of its members. There have been no recent public reports indicating proxy contests or activist investor actions influencing Health Catalyst's decision-making processes.

Understanding Health Catalyst's Voting Structure

Health Catalyst's voting power is centralized through its one-share-one-vote policy. This structure ensures that influence is directly proportional to share ownership.

• Each share of common stock holds one vote.
• Stockholders do not have cumulative voting rights for director elections.
• Special meetings can only be called by the board of directors.
• Amendments to key company documents require significant stockholder approval.
• The board can amend bylaws with a majority vote.

Health Catalyst Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

In recent years, the company has focused on strategic growth through acquisitions and key leadership appointments. These moves aim to bolster its market presence and integrate new capabilities, reflecting an evolving healthcare technology landscape. The company's ownership structure is influenced by these strategic decisions and broader market trends.

The company has seen significant activity in its leadership and strategic direction over the past few years. These changes are designed to enhance its capabilities in areas like artificial intelligence and patient engagement, aligning with industry-wide shifts towards data-driven healthcare solutions.

Strategic Acquisitions

The company completed three acquisitions in 2024 and one in early 2025, with an average acquisition cost of $72.5 million. These acquisitions, including Upfront Healthcare Services for $86 million, aim to expand its patient engagement and acquisition offerings.

Leadership Enhancements

Key leadership roles have been filled to drive innovation, such as the promotion of Dr. Daniel Samarov to Chief AI Officer in early 2025. New members have also joined the leadership team and the Board of Directors, strengthening the company's strategic oversight.

Market Alignment with AI

The healthcare data analytics market is projected to reach $94.86 billion by the end of 2025, with AI and machine learning contributing 30% to this growth. The company's focus on AI-driven solutions, like its Ignite Spark™ offering, positions it to benefit from this trend.

Financial Outlook

The company reported $307 million in total revenue for the full year 2024 and projects approximately $335 million for 2025. It anticipates continued top-line growth acceleration, with its Technology segment expected to outperform the overall business.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE